P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
Paul G. Richardson,Arnon Nagler,Dina Ben-Yehuda,Ashraf Badros,Parameswaran Hari,Roman Hájek,Ivan Spicka,Hakan Kaya,Richard Leblanc,Sung-Soo Yoon,Kihyun Kim,Joaquin Martinez-Lopez,Moshe Mittelman,Ofer Shpilberg,Paul Blake,Teru Hideshima,Kathleen Colson,Jacob P. Laubach,Irene M. Ghobrial,Merav Leiba,Moshe E. Gatt,Peter Sportelli,Michael Chen,Kenneth C. Anderson +23 more
TL;DR: Findings demonstrate no PFS benefit from the addition of perifosine to bortezomib‐dexamethasone in this study of relapsed/refractory MM, but comparable safety and OS.
Journal ArticleDOI
SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)
Saad Z. Usmani,Rachael Sexton,Sikander Ailawadhi,Jatin J. Shah,Natalie S. Callander,Todd M. Zimmerman,Jason Valent,Michael Rosenzweig,Brea Lipe,Jeffrey A. Zonder,Sandi Fredette,Brian G.M. Durie,Antje Hoering,S. Vincent Rajkumar,Paul G. Richardson,Robert Z. Orlowski +15 more
TL;DR: A randomized Phase I/II trial was designed to evaluate the efficacy of adding immunotherapy into the first line for HRMM patients, comparing lenalidomide, bortezomib and dexamethasone (RVD) with or without addition of elotuzumab (Elo), a humanized monoclonal antibody that binds to SLAMF7/CS1.
Journal ArticleDOI
Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.
Paul G. Richardson,Angela R. Smith,Nancy A. Kernan,Leslie Lehmann,Robert J. Ryan,Stephan A. Grupp +5 more
TL;DR: The results highlight the importance of continued defibrotide therapy until resolution of VOD/SOS signs and symptoms, as currently indicated in the approved product labels, which may occur beyond the recommended minimum of 21 days.
The use of defibrotide in BMT-associated veno-occlusive disease
Paul G. Richardson,A. Krishnan,C Wheeler,Lois Ayash,D. Hoppensteadt,J. Fareed,Lowell E. Schnipper,Donald Kufe,E. I. . Freii,Anthony D. Elias +9 more
Journal ArticleDOI
TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.
Toshiaki Hayashi,Teru Hideshima,Klaus Podar,Paul G. Richardson,Olivier Munoz,Makoto Hamasaki,Kenji Ishitsuka,Hiroshi Yasui,Alison Murphy,Glenn Mcenroe,Sarvajit Chakravarty,Sundeep Dugar,Linda S. Higgins,Dharminder Chauhan,Kenneth C. Anderson +14 more
TL;DR: SD-208 works, at least in part, by blocking TGF-β1-triggered nuclear accumulation of Smad2/3 and hypoxia-inducible factor 1α, as well as related production of IL-6 and VEGF, respectively.